Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
Molecular Cancer Research : MCR
|
November 20, 2021
Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia
Florencia Rago, Lindsey Ulkus Rodrigues, Megan Bonney, et al.
Plos One
|
November 9, 2013
Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors
Simon Wöhrle, Andreas Weiss, Moriko Ito, et al.
Nature Communications
|
August 22, 2019
PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma
Melusine Bleu, Swann Gaulis, Rui Lopes, et al.
Molecular Oncology
|
April 23, 2009
MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S
Jean Bénard, Gilda Raguénez, Audrey Kauffmann, et al.
Nature Medicine
|
June 29, 2010
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity
Frédéric Chibon, Pauline Lagarde, Sébastien Salas, et al.
Cancer Research
|
November 19, 2015
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition
Barbara Herkert, Audrey Kauffmann, Sandra Mollé, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 8, 2017
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf<sup>-/-</sup> mouse model
Emilie A Chapeau, Agnieszka Gembarska, Eric Y Durand, et al.
Molecular Cancer Therapeutics
|
June 2, 2012
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations
Saskia M Brachmann, Julia Kleylein-Sohn, Swann Gaulis, et al.
Cancer Discovery
|
September 25, 2012
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor
Vito Guagnano, Audrey Kauffmann, Simon Wöhrle, et al.
Molecular Cancer Therapeutics
|
August 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss, Flavia Adler, Alexandra Buhles, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
Molecular Cancer Research : MCR
|
November 20, 2021
Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia
Florencia Rago, Lindsey Ulkus Rodrigues, Megan Bonney, et al.
Plos One
|
November 9, 2013
Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors
Simon Wöhrle, Andreas Weiss, Moriko Ito, et al.
Nature Communications
|
August 22, 2019
PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma
Melusine Bleu, Swann Gaulis, Rui Lopes, et al.
Molecular Oncology
|
April 23, 2009
MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S
Jean Bénard, Gilda Raguénez, Audrey Kauffmann, et al.
Nature Medicine
|
June 29, 2010
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity
Frédéric Chibon, Pauline Lagarde, Sébastien Salas, et al.
Cancer Research
|
November 19, 2015
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition
Barbara Herkert, Audrey Kauffmann, Sandra Mollé, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 8, 2017
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf<sup>-/-</sup> mouse model
Emilie A Chapeau, Agnieszka Gembarska, Eric Y Durand, et al.
Molecular Cancer Therapeutics
|
June 2, 2012
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations
Saskia M Brachmann, Julia Kleylein-Sohn, Swann Gaulis, et al.
Cancer Discovery
|
September 25, 2012
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor
Vito Guagnano, Audrey Kauffmann, Simon Wöhrle, et al.
Molecular Cancer Therapeutics
|
August 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss, Flavia Adler, Alexandra Buhles, et al.
Page
of 5